Pelthos Therapeutics Inc. (New York Stock Exchange Arca:PTHS)
| Market Cap | $25.08M-76.8% |
| Revenue (ttm) | $51.29M+592.6% |
| Net Income | -$63.21M-168.1% |
| EPS | -$18.62+49.9% |
| Shares Out | 3.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 63,962 |
| Open | $6.96 |
| Previous Close | $6.99 |
| Day's Range | $6.38 - $7.21 |
| 52-Week Range | $6.02 - $31.62 |
| Beta | 3.11 |
| Analysts | Buy |
| Price Target | $38.75(+507.37%) |
| Earnings Date | Mar 18, 2027 |
About PTHS
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating PTHS in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 18, 2027Earnings report
$PTHS stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in PTHS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by PTHS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
PTHS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
PTHS Revenue by Segment
| Commercial operations | $15.21M | 78.91% |
| Change in fair value of convertible debt | $4.07M | 21.09% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New PTHS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to PTHS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in PTHS
| VTIVanguard Morningstar Total Stock Market ETF | $577.85K |
| VXFVanguard Extended Market ETF | $151.60K |
| IWCiShares Micro-Cap ETF | $31.66K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from PTHS’s recent data — informational, not investment advice
What’s Behind the Score
News check: Analyst downgrades and fair value cuts dominate, though revenue growth in ZELSUVMI and Oppenheimer's maintained outperform partially offset bearish sentiment.
